Results 81 to 90 of about 42,546 (247)

Efeito do canabidiol sobre a reconsolidação da memória de medo ao contexto: envolvimento dos receptores CB1 do córtex pré-límbico [PDF]

open access: yes, 2014
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia, Florianópolis, 2014.A busca por drogas que prejudicam a reconsolidação de memórias traumáticas pode ter um impacto ...
Stern, Cristina Aparecida Jark
core  

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

microRNA-128 mediates CB1 expression and regulates NF-KB/p-JNK axis to influence the occurrence of diabetic bladder disease

open access: yesJournal of Translational Medicine, 2020
Background Diabetic bladder disease is common complications of diabetes, its symptoms are diverse, can be due to different stages. In this study we investigate the mechanism of miR-128 targeting CB1 expression to mediate the occurrence of diabetic ...
Xin Gou   +7 more
doaj   +1 more source

Metabolic Profiling of CB1 Neutral Antagonists [PDF]

open access: yes, 2017
PIMSR is among the first neutral antagonists for the CB1R and was demonstrated pharmacologically to bind to the CB1R, yet not alter calcium flux. It was further shown computationally to be able to stabilize both the active and inactive states of CB1R revealing the molecular interactions that mechanistically afford the property of neutral antagonism ...
Herbert H, Seltzman   +6 more
openaire   +2 more sources

A lesão dopaminérgica como modelo de estágio pré-motor da doença de Parkinson: efeitos do antagonismo do receptor CB1 [PDF]

open access: yes, 2012
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia, Florianópolis, 2010Além dos sinais motores clássicos, a doença de Parkinson é caracterizada por déficits cognitivos e ...
Tadaiesky, Meigy Tavares
core  

Synaptic localization of CB1 in V1.

open access: yes, 2013
(A) Double immunofluorescent staining of CB1 (magenta) and MAP2 (green) in the upper layer of V1. CB1-positive varicosities presumably contact MAP2-positive dendrites (white arrowheads) and soma (asterisk, yellow arrowheads). Scale, 3 µm.
Katsuro Kameyama (290005)   +5 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

open access: yesPLoS ONE, 2011
It is well known that acute challenges with psychostimulants such as amphetamine affect impulsive behavior. We here studied the pharmacology underlying the effects of amphetamine in two rat models of impulsivity, the 5-choice serial reaction time task (5-
Joost Wiskerke   +4 more
doaj   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade   +7 more
wiley   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux   +26 more
wiley   +1 more source

Home - About - Disclaimer - Privacy